The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review-Reference-Cited by-同舟云学术

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

Published:2022-03-20 Issue:5 Volume:13 Page:847-872
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Wilding John P. H.^ORCID,Evans Marc,Fernando Kevin,Gorriz Jose Luis,Cebrian Ana,Diggle Jane,Hicks Debbie,James June,Newland-Jones Philip,Ali Amar,Bain Stephen,Da Porto Andrea,Patel Dipesh,Viljoen Adie,Wheeler David C.,Del Prato Stefano

Funder

Mundipharma Research Limited

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-022-01228-w.pdf

Reference117 articles.

1. Wilding J, Fernando K, Milne N, et al. SGLT2 inhibitors in Type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9(5):1757–73.

2. Ali A, Bain S, Hicks D, Newland, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10(5):1595–622.

3. Wheeler DC, James J, Patel D, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in Type 2 diabetes. Diabetes Ther. 2020;11(12):2757–74.

4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic Osteodystrophy;Endocrinology Research and Practice;2024-07-03

2. Bexagliflozin in type 2 diabetes: a profile of its use;Drugs & Therapy Perspectives;2024-07

3. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease;Annals of Internal Medicine;2024-06

4. Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review;Medicina;2024-05-30

5. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review;Diabetes Therapy;2024-04-05